Think a lost weekend is bad, what about a lost decade?
Derek Lowe writes In the Pipeline that a large majority of Big Pharma underperformed the S&P index for the last 10 years. The original post was inspired by Jeffrey Kindler's retirment last week and simply noted that Pfizer was one of those (not the only) big underperformers. And, that despite all the merger activity it had undertaken to try to shore up revenues and make up for pipeline failures, it had been unable to do so.
The conclusion? Nothing makes up for a bad pipeline at Pfizer, Lilly, Merck, BMS or anywhere else. Lost revenue unreplaced is lost revenue.
Posted by Bruce Lehr December 13th 2010.